Orticumab not checked
Abcentra · MLDL1278a · BI204
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total · 1 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- Tested for
- Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease, Myocardial Infarct, Atherosclerotic Coronary Vascular Disease
- Main trialPhase 2
- “The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study…”In the company’s words, NCT06927739 on ClinicalTrials.gov
- Other names
- MLDL1278a · BI204
Other drugs for Inflammation
- SatralizumabRoche · Phase 3
- Group ACYW135 Meningococcal Conjugate VaccineSinovac Biotech Co., Ltd · Phase 3
- EculizumabAlexion Pharmaceuticals, Inc. · Phase 3
- RuxolitinibIncyte · Novartis · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- PovorcitinibIncyte Corporation · Phase 3
Coming up1
- 8 Feb 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 8 Feb 2027 | Focused Orticumab Research for Treating Inflammation in Coronary Arteries | |
| Phase 2Completed | 11 Nov 2022 | A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026